ORIGINAL RESEARCH
Accepted on 06 Oct 2025
Comparative Cardiovascular Risks of Canagliflozin and selective SGLT2 Inhibitors in Type 2 Diabetes
doi 10.3389/fphar.2025.1686851
- Frontiers in Pharmacology
- Cardiovascular and Smooth Muscle Pharmacology
- Research Topics
- Cardiometabolic Crosstalk: Mechanisms, Modulators, and Therapeutics in Diabetes-Induced Cardiovascular Disease
Cardiometabolic Crosstalk: Mechanisms, Modulators, and Therapeutics in Diabetes-Induced Cardiovascular Disease
826
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
You will be redirected to our submission process.